Acusphere Announces that Imagify(TM) Safety and ECHO Reader Training Data Will Be Presented at EuroEcho 2007
Thursday December 6, 4:05 pm ET
Two peer-reviewed studies to be shared with leading echocardiologists worldwide
WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ:ACUS - News) today announced today that Dr. Arian Pano, M.D., Acusphere's Internal Medical Monitor, is scheduled to present a poster entitled "Evaluation of ECG-Related Safety of Perflubutane Polymer Microspheres (PPM) Injectable Suspension in Chronic Stable Angina Patients Undergoing Stress Echocardiography in RAMP -1 and -2 Trials," at EuroECHO 2007 in Lisbon, Portugal. PPM for injectable suspension is the generic name for ImagifyTM (IND AI-700). Dr. Pano’s presentation concludes that chronic stable angina patients evaluated in Acusphere’s Phase 3 clinical trials did not experience a significant increase in the risk of arrhythmia and ischemic ECG changes with use of Imagify during Rest or Dipyridamole Stress ECHO. The poster will be presented at the Lisbon Congress Center, on Friday, December 7, 2007, beginning at 10:00 AM local time. Dr. Pano served as the internal medical monitor during the Phase 3 clinical trials for Imagify. The conclusions in this abstract result from a collaboration between investigators at Massachusetts General Hospital Heart Center and the Duke Medical Center EKG Core Laboratory.
Dr. Richard Walovitch, Acusphere’s Senior Vice President of Clinical Research, said, “We are very pleased to have the opportunity to present this important safety data from our Phase 3 clinical trials for Imagify at one of the leading events for echocardiologists throughout the world. We are very excited with the positive outcome that this peer-reviewed analysis presents.”
In addition, one of the ECHO blinded readers in Acusphere’s Phase 3 clinical trials, Dr. Harald Becher, Director, Cardiac Ultra-sound Unit, John Radcliffe Hospital in Oxford, England, will present at EuroECHO 2007 on the same day and time another poster on Imagify entitled “Impact of Focused Training on Increased Sensitivity and Consistency of Perfusion Stress Contrast.”
Added Dr. Walovitch, “Dr. Becher’s presentation provides insight into how to teach cardiologists strategies to optimize Imagify image interpretation. We are confident that these findings will be quite useful as we move forward with our commercialization plans for Imagify.”
EuroEcho is the major annual educational and research meeting in cardiovascular ultrasound in Europe, showcasing some of the most important scientific data on echocardiography and attracting participants from around the world.
In the RAMP-1 and -2 trials, Imagify was well-tolerated with the majority of adverse events (AEs) reported being mild in intensity, transient, and resolved without residual effects. The most common AEs reported were headache, chest pain or discomfort, nausea and flushing and occurred following dipyridamole dosing (an alternative to exercise stress).
biz.yahoo.com |
